BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tergast TL, Kimmann M, Laser H, Gerbel S, Manns MP, Cornberg M, Maasoumy B. Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. Aliment Pharmacol Ther. 2019;50:696-706. [PMID: 31373713 DOI: 10.1111/apt.15439] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Guo H, Xiao J, Wang Y, Zhang M, Zhuge Y, Zhang F. Increase in Free Hepatic Venous Pressure Response to Beta-Blockers Predicts Variceal Bleeding in Cirrhotic Patients. Biomed Res Int 2021;2021:5587566. [PMID: 33997022 DOI: 10.1155/2021/5587566] [Reference Citation Analysis]
2 Pfisterer N, Unger LW, Reiberger T. Clinical algorithms for the prevention of variceal bleeding and rebleeding in patients with liver cirrhosis. World J Hepatol 2021; 13(7): 731-746 [PMID: 34367495 DOI: 10.4254/wjh.v13.i7.731] [Reference Citation Analysis]
3 Jachs M, Hartl L, Simbrunner B, Bauer D, Paternostro R, Scheiner B, Schwabl P, Stättermayer AF, Pinter M, Eigenbauer E, Quehenberger P, Trauner M, Reiberger T, Mandorfer M. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00726-6. [PMID: 34256145 DOI: 10.1016/j.cgh.2021.07.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Bultas AC, Teshome B, Richter SK, Schafers S, Cooke E, Call WB. Use of Nonselective β-Blockers in Patients With End-Stage Liver Disease and Select Complications. Ann Pharmacother 2020;54:583-93. [DOI: 10.1177/1060028019893092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Labenz C, Nagel M, Toenges G, Kuchen R, Schattenberg JM, Hilscher M, Huber Y, Marquardt JU, Labenz J, Galle PR, Wörns MA. Impact of non-selective ß-blockers on hepatic encephalopathy in patients with liver cirrhosis. Eur J Intern Med 2020;82:83-9. [PMID: 32873457 DOI: 10.1016/j.ejim.2020.08.022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Garcia-Pagan JC, Francoz C, Montagnese S, Senzolo M, Mookerjee RP. Management of the major complications of cirrhosis: Beyond guidelines. J Hepatol 2021;75 Suppl 1:S135-46. [PMID: 34039484 DOI: 10.1016/j.jhep.2021.01.027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
7 Bernal W, Karvellas C, Saliba F, Saner FH, Meersseman P. Intensive care management of acute-on-chronic liver failure. J Hepatol 2021;75 Suppl 1:S163-77. [PMID: 34039487 DOI: 10.1016/j.jhep.2020.10.024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
9 Jakab SS, Garcia-tsao G. Evaluation and Management of Esophageal and Gastric Varices in Patients with Cirrhosis. Clinics in Liver Disease 2020;24:335-50. [DOI: 10.1016/j.cld.2020.04.011] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Mandorfer M, Reiberger T. Editorial: pressure to close the therapeutic window of non-selective beta blockers? Aliment Pharmacol Ther 2019;50:957-8. [PMID: 31591778 DOI: 10.1111/apt.15472] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Rabiee A, Garcia‐tsao G, Tapper EB. Nonselective Beta‐Blockers in Portal Hypertension: Why, When, and How? Clinical Liver Disease. [DOI: 10.1002/cld.1182] [Reference Citation Analysis]
12 Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: Evidence-based indications and limitations. JHEP Rep 2020;2:100063. [PMID: 32039404 DOI: 10.1016/j.jhepr.2019.12.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
13 Haque LY, Garcia-Tsao G. A Historical Overview of Spontaneous Bacterial Peritonitis: From Rare to Resistant. Clin Liver Dis (Hoboken) 2021;18:63-75. [PMID: 34745584 DOI: 10.1002/cld.1122] [Reference Citation Analysis]
14 Tergast TL, Maasoumy B. Editorial: pressure to close the therapeutic window of non-selective beta blockers? Authors' reply. Aliment Pharmacol Ther 2019;50:958-60. [PMID: 31591774 DOI: 10.1111/apt.15489] [Reference Citation Analysis]
15 Pfisterer N, Schmidbauer C, Riedl F, Maieron A, Stadlbauer V, Hennlich B, Schwarzer R, Puespoek A, Bucsics T, Effenberger M, Bota S, Gschwantler M, Peck-Radosavljevic M, Mandorfer M, Madl C, Trauner M, Reiberger T. Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. Wien Klin Wochenschr. 2021;133:421-431. [PMID: 33270161 DOI: 10.1007/s00508-020-01769-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Wang SF, Huang YT, Huang CH, Chang SH, Lin CY. Fibrosis index predicts variceal bleeding and reduces need for nonselective beta-blocker in compensated cirrhosis with initial small esophageal varices without red-color sign. Ann Transl Med 2020;8:1223. [PMID: 33178755 DOI: 10.21037/atm-20-2444] [Reference Citation Analysis]
17 Lin FP, Visina JM, Bloomer PM, Dunn MA, Josbeno DA, Zhang X, Clemente-Sanchez A, Tevar AD, Hughes CB, Jakicic JM, Duarte-Rojo A. Prehabilitation-Driven Changes in Frailty Metrics Predict Mortality in Patients With Advanced Liver Disease. Am J Gastroenterol 2021. [PMID: 34313620 DOI: 10.14309/ajg.0000000000001376] [Reference Citation Analysis]